Spotlight on Nephrology

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Patient Selection and Individualization
Neera Dahl, MD, PhD
Medical Education Resources (MER)

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Patient Selection and Individualization

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Apply evidence-based principles to select patients with ADPKD who are appropriate for disease-modifying therapy.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the first of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Assessing risk for rapid progression of ADPKD
    • Imaging modalities
    • Criteria and predictors
    • Mayo classification model and others
  • Clinical trials in pharmacologic treatment of ADPKD
    • Efficacy and safety
  • Patient selection
  • REMS and other considerations before initiating therapy

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Gary Israel, MD
Section Chief: Abdomen
Professor of Radiology
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Gary Israel, MD
Dr. Israel has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-173-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Apply evidence-based principles to select patients with ADPKD who are appropriate for disease-modifying therapy.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the first of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Assessing risk for rapid progression of ADPKD
    • Imaging modalities
    • Criteria and predictors
    • Mayo classification model and others
  • Clinical trials in pharmacologic treatment of ADPKD
    • Efficacy and safety
  • Patient selection
  • REMS and other considerations before initiating therapy

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Gary Israel, MD
Section Chief: Abdomen
Professor of Radiology
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Gary Israel, MD
Dr. Israel has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-173-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Nephrology Presentations

Medical Education Resources (MER)
Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Monitoring and Risk Mitigation

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Monitoring and Risk Mitigation

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Employ strategies to mitigate risk when initiating and monitoring pharmacologic therapy for ADPKD.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the third of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Milestones and steps for REMS requirements
  • Mitigation elements
    • Laboratory monitoring
  • Enhancing adherence in patients with ADPKD
  • REMS and COVID-19

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-175-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Employ strategies to mitigate risk when initiating and monitoring pharmacologic therapy for ADPKD.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the third of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Milestones and steps for REMS requirements
  • Mitigation elements
    • Laboratory monitoring
  • Enhancing adherence in patients with ADPKD
  • REMS and COVID-19

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-175-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Medical Education Resources (MER)
Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Successful Initiation of Pharmacologic Therapy for ADPKD

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Successful Initiation of Pharmacologic Therapy for ADPKD

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Describe the optimal use of REMS programs to improve safety and patient outcomes.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the second of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Initiating pharmacologic therapy
  • REMS rationale and objectives for treatment of ADPKD
  • Strategies for patient counseling
  • Teamwork and collaboration: patient, nephrologist, pharmacist, and other health care providers

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Lena DeVietro, PharmD
Multi-Specialty Clinical Pharmacist
Yale New Haven Hospital
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Lena DeVietro, PharmD
Dr. DeVietro has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-174-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Describe the optimal use of REMS programs to improve safety and patient outcomes.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the second of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Initiating pharmacologic therapy
  • REMS rationale and objectives for treatment of ADPKD
  • Strategies for patient counseling
  • Teamwork and collaboration: patient, nephrologist, pharmacist, and other health care providers

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Lena DeVietro, PharmD
Multi-Specialty Clinical Pharmacist
Yale New Haven Hospital
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Lena DeVietro, PharmD
Dr. DeVietro has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-174-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Medical Education Resources (MER)
Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Patient Selection and Individualization

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Patient Selection and Individualization

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Apply evidence-based principles to select patients with ADPKD who are appropriate for disease-modifying therapy.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the first of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Assessing risk for rapid progression of ADPKD
    • Imaging modalities
    • Criteria and predictors
    • Mayo classification model and others
  • Clinical trials in pharmacologic treatment of ADPKD
    • Efficacy and safety
  • Patient selection
  • REMS and other considerations before initiating therapy

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Gary Israel, MD
Section Chief: Abdomen
Professor of Radiology
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Gary Israel, MD
Dr. Israel has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-173-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Apply evidence-based principles to select patients with ADPKD who are appropriate for disease-modifying therapy.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the first of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Assessing risk for rapid progression of ADPKD
    • Imaging modalities
    • Criteria and predictors
    • Mayo classification model and others
  • Clinical trials in pharmacologic treatment of ADPKD
    • Efficacy and safety
  • Patient selection
  • REMS and other considerations before initiating therapy

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Gary Israel, MD
Section Chief: Abdomen
Professor of Radiology
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Gary Israel, MD
Dr. Israel has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-173-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

1.00 CME
Annenberg Center for Health Sciences at Eisenhower
Research Updates in Gout: Improving Response Rate to Therapy

Research Updates in Gout: Improving Response Rate to Therapy

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: February 12, 2021
Expires: February 11, 2022
60 minutes to complete

Accredited By

Target Audience

Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.

Learning Objectives

  • Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
  • Summarize the latest evidence related to complications associated with gout
  • Incorporate evidence-based research into clinical practice

Activity Description

OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction to this CME activity by touching on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger focuses on 2 abstracts presented at ACR Convergence 2020 concerning gout-related comorbidities, particularly cardiovascular disease. In module 2, Dr. Mandell focuses on 2 abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the systemic nature of gout; 1 abstract focuses on heart failure, while the other focuses on the lumbar spine.

CONTENT AREAS

  • Systemic burden of gout
  • Gout comorbidities
  • Allopurinol
  • Febuxostat
  • Pegloticase

Statement of Educational Need

  • Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
  • Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
  • Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs

Agenda

Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:

  1. Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
  2. Faculty reviews study methodology [1 min]
    1. For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
  3. Faculty summarizes key findings [3-4 min]
    1. How the data advances the current treatment landscape/paradigms
    2. How the data should be positioned among ongoing research
    3. How the data connects with current research imperatives
    4. Clinical significance/implications for current knowledge or practice
    5. Data one might be expected from the trial in the future
  4. Faculty provides commentary [5-8 min]

Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.

Faculty

Brian Mandell, MD, PhD
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio


Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech

Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Statement of Commercial Support

This activity is supported by an educational grant from Horizon Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information for Questions About the Activity

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: February 12, 2021
Expires: February 11, 2022
60 minutes to complete

Accredited By

Target Audience

Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.

Learning Objectives

  • Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
  • Summarize the latest evidence related to complications associated with gout
  • Incorporate evidence-based research into clinical practice

Activity Description

OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction to this CME activity by touching on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger focuses on 2 abstracts presented at ACR Convergence 2020 concerning gout-related comorbidities, particularly cardiovascular disease. In module 2, Dr. Mandell focuses on 2 abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the systemic nature of gout; 1 abstract focuses on heart failure, while the other focuses on the lumbar spine.

CONTENT AREAS

  • Systemic burden of gout
  • Gout comorbidities
  • Allopurinol
  • Febuxostat
  • Pegloticase

Statement of Educational Need

  • Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
  • Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
  • Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs

Agenda

Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:

  1. Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
  2. Faculty reviews study methodology [1 min]
    1. For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
  3. Faculty summarizes key findings [3-4 min]
    1. How the data advances the current treatment landscape/paradigms
    2. How the data should be positioned among ongoing research
    3. How the data connects with current research imperatives
    4. Clinical significance/implications for current knowledge or practice
    5. Data one might be expected from the trial in the future
  4. Faculty provides commentary [5-8 min]

Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.

Faculty

Brian Mandell, MD, PhD
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio


Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech

Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Statement of Commercial Support

This activity is supported by an educational grant from Horizon Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information for Questions About the Activity

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

0.50 CME / CE
Clinical Care Options
Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices

Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices

Start

Activity Details

Free CME/CE
0.5 AMA PRA Category 1 Credit(s)™/
AAPA Category 1 CME credit(s)
Released: January 8, 2021
Expires: January 7, 2022
30 minutes to complete

Accredited By

Jointly Provided By

Target Audience

This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.

Learning Objectives

  • Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
  • Outline risks associated with delayed intervention in patients with diabetic eye disease.
  • Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
  • Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.

Activity Description

This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.

Statement of Educational Need

The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1

With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.

1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.

2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682

3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009

Agenda

  • Latino/Hispanic population growth in the US
  • Healthcare disparities
  • Diabetic eye disease risk and complications
  • Eye exam frequency recommendations
  • Triage and other practical diagnostic challenges
  • Screening and exam recommendations
  • Evidence-based best practices for diagnosing diabetic eye disease
  • The most commonly performed procedure in ophthalmology
  • Anti-VEGF treatments for DME
  • Anti-VEGF treatments for DR
  • Anti-VEGF treatments for NPDR

Faculty

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Conflict of Interest Policy/Disclosure Statement

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.

Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com

Activity Details

Free CME/CE
0.5 AMA PRA Category 1 Credit(s)™/
AAPA Category 1 CME credit(s)
Released: January 8, 2021
Expires: January 7, 2022
30 minutes to complete

Accredited By

Jointly Provided By

Target Audience

This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.

Learning Objectives

  • Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
  • Outline risks associated with delayed intervention in patients with diabetic eye disease.
  • Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
  • Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.

Activity Description

This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.

Statement of Educational Need

The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1

With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.

1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.

2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682

3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009

Agenda

  • Latino/Hispanic population growth in the US
  • Healthcare disparities
  • Diabetic eye disease risk and complications
  • Eye exam frequency recommendations
  • Triage and other practical diagnostic challenges
  • Screening and exam recommendations
  • Evidence-based best practices for diagnosing diabetic eye disease
  • The most commonly performed procedure in ophthalmology
  • Anti-VEGF treatments for DME
  • Anti-VEGF treatments for DR
  • Anti-VEGF treatments for NPDR

Faculty

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Conflict of Interest Policy/Disclosure Statement

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.

Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com

1.00 CME / CNE / CPE
AcademicCME
Advances in the Management of Acute and Chronic Hyperkalemia

Advances in the Management of Acute and Chronic Hyperkalemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

0.50 CME
University of Florida College of Medicine
The Clinical Significance of Imaging in the Management of ADPKD

The Clinical Significance of Imaging in the Management of ADPKD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credits
Released: May 27, 2020
Expires: May 26, 2021
30 minutes to complete

Target Audience

This activity has been designed to meet the educational needs of radiologists and other health care professionals involved in the diagnosis, treatment and management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Overview

This Expert Exchange webcast is designed to help clinicians better understand the importance of radiologic imaging in the clinical management of patients affected by ADPKD.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Recognize the significance of total kidney volume (TKV) in ADPKD
  • Summarize the methods for assessing TKV
  • Recognize atypical vs. typical presentations of PKD
  • Summarize clinical decision-making steps regarding treatment decisions

Faculty

Bohyun Kim, MD, PhD
Chief, GU Section
Professor of Radiology
Mayo Clinic
Rochester, MN


Anjay Rastogi, MD, PhD
Director, PKD Program and CORE Kidney Program
Professor and Clinical Chief, Nephrology
UCLA Geffen School of Medicine
Los Angeles, CA


Financial Support

This activity has been supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Providers

Jointly provided by the University of Florida College of Medicine and Novus Medical Education.

Joint Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Novus Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education

The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

The University of Florida College of Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to UF COM policy. UF COM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Dr. Kim reports no relevant financial relationships to disclose.
Dr. Rastogi reports the following relevant financial relationships:

  • Speakers Bureau/Advisory Board - Genzyme/Sanofi, Otsuka
  • Research Support - Kadmon, Reata Pharmaceuticals, Sanofi

Planners and Managers
The UF COM and Novus Medical Education planners and managers have nothing to disclose.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

  • Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the pre-test.
  • View the webcast.
  • Complete the post-test and evaluation.
  • Physicians who receive a grade of 80% or better on the post-test and complete the evaluation will receive a CME certificate.
  • All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CME Provider

The University of Florida College of Medicine can be contacted at cme-mail@ufl.edu or 352.733.0064.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credits
Released: May 27, 2020
Expires: May 26, 2021
30 minutes to complete

Target Audience

This activity has been designed to meet the educational needs of radiologists and other health care professionals involved in the diagnosis, treatment and management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Overview

This Expert Exchange webcast is designed to help clinicians better understand the importance of radiologic imaging in the clinical management of patients affected by ADPKD.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Recognize the significance of total kidney volume (TKV) in ADPKD
  • Summarize the methods for assessing TKV
  • Recognize atypical vs. typical presentations of PKD
  • Summarize clinical decision-making steps regarding treatment decisions

Faculty

Bohyun Kim, MD, PhD
Chief, GU Section
Professor of Radiology
Mayo Clinic
Rochester, MN


Anjay Rastogi, MD, PhD
Director, PKD Program and CORE Kidney Program
Professor and Clinical Chief, Nephrology
UCLA Geffen School of Medicine
Los Angeles, CA


Financial Support

This activity has been supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Providers

Jointly provided by the University of Florida College of Medicine and Novus Medical Education.

Joint Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Novus Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education

The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

The University of Florida College of Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to UF COM policy. UF COM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Dr. Kim reports no relevant financial relationships to disclose.
Dr. Rastogi reports the following relevant financial relationships:

  • Speakers Bureau/Advisory Board - Genzyme/Sanofi, Otsuka
  • Research Support - Kadmon, Reata Pharmaceuticals, Sanofi

Planners and Managers
The UF COM and Novus Medical Education planners and managers have nothing to disclose.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

  • Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the pre-test.
  • View the webcast.
  • Complete the post-test and evaluation.
  • Physicians who receive a grade of 80% or better on the post-test and complete the evaluation will receive a CME certificate.
  • All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CME Provider

The University of Florida College of Medicine can be contacted at cme-mail@ufl.edu or 352.733.0064.